The company uses genomically recoded strains of bacteria to incorporate non-standard amino acids into proteins, which enhances their potency, stability, and targeted delivery. GRO Biosciences is focused on developing protein therapeutics for diabetes, growth disorders, and autoimmunity. It operates out of the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.